LCB 2183

a pteridinone that is an anti-allergic and potential anti-asthma compound; inhibits the inflammation associated with oxazolone-induced contact sensitivity

Also Known As:

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Pneumonia (Pneumonitis) 08/25/1995 - "These results demonstrate that LCB 2183 could be effective in the treatment of airway hyperreactivity and pulmonary inflammation." 08/25/1995 - "LCB 2183 inhibits tracheal hyperreactivity and pulmonary inflammation in mouse airways."
2.	Inflammation (Inflammations) 08/01/1994 - "LCB 2183 acts early in the cascade of events leading to inflammation, since the initiation phase of the response was inhibited; nonetheless, an effect of the drug on the late acting inflammatory cells cannot be ruled out. " 08/01/1994 - "LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity."
3.	Contact Dermatitis (Eczema, Contact) 08/01/1994 - "Both the early and late components of oxazolone-induced contact sensitivity were inhibited by oral administration of LCB 2183 in a dose-dependent manner. " 08/01/1994 - "LCB 2183, an anti-allergic and potential anti-asthma compound, has been investigated for its ability to inhibit contact sensitivity in the mouse. " 08/01/1994 - "LCB 2183 inhibits the inflammation associated with oxazolone-induced contact sensitivity."
4.	Asthma (Bronchial Asthma) 08/01/1994 - "LCB 2183, an anti-allergic and potential anti-asthma compound, has been investigated for its ability to inhibit contact sensitivity in the mouse. "

Related Drugs and Biologics

1.	Anti-Allergic Agents (Antiallergic Agents)
2.	Oxazolone

Related Therapies and Procedures

1.	Oral Administration